KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Capital Expenditures (2016 - 2025)

Biolife Solutions (BLFS) has disclosed Capital Expenditures for 16 consecutive years, with -$5.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 785.04% to -$5.2 million in Q4 2025 year-over-year; TTM through Sep 2025 was $6.0 million, a 582.42% increase, with the full-year FY2024 number at $3.2 million, up 798.89% from a year prior.
  • Capital Expenditures was -$5.2 million for Q4 2025 at Biolife Solutions, down from $5.1 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $5.1 million in Q3 2025 to a low of -$5.2 million in Q4 2025.
  • A 5-year average of $224263.2 and a median of $175000.0 in 2025 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 1698.78% in 2021; the steepest drop was 3547.06% in 2021.
  • Biolife Solutions' Capital Expenditures stood at -$108000.0 in 2021, then plummeted by 995.37% to -$1.2 million in 2022, then crashed by 213.19% to -$3.7 million in 2023, then soared by 120.57% to $762000.0 in 2024, then crashed by 785.04% to -$5.2 million in 2025.
  • Per Business Quant, the three most recent readings for BLFS's Capital Expenditures are -$5.2 million (Q4 2025), $5.1 million (Q3 2025), and -$85000.0 (Q2 2025).